Citizens JMP Reiterates Market Outperform Rating on Inovio Pharmaceuticals (INO)

Citizens JMP analyst Roy Buchanan reiterated a Market Outperform rating and $12.00 price target on Inovio Pharmaceuticals (NASDAQ: INO).

The analyst commented, “Stability testing for the device array is underway, cash is expected to be sufficient beyond BLA acceptance; we reiterate our Market Outperform rating and risk-adjusted, DCF-derived $12 price target on Inovio Pharmaceuticals. Inovio reported 1Q25 results slightly ahead of our and consensus estimates on lower-than-anticipated expenses. Cash at quarter-end was $68M and management reiterated runway guidance into 1Q26. Inovio also reiterated that it remains on track for starting the BLA submission for INO-3107 to treat recurrent respiratory papillomatosis (RRP) such that it can be filed by YE. We continue to expect INO-3107 to gain priority review due to the Breakthrough Therapy designation. While the new FDA administration is a wild card, management's discussions with the agency to date have been consistent with prior communications.”

For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.

Shares of Inovio Pharmaceuticals closed at $1.92 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating